NCT03581292 2026-04-13
Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
National Cancer Institute (NCI)
Phase 2 Active not recruiting
National Cancer Institute (NCI)
National Cancer Institute (NCI)
NRG Oncology
Mayo Clinic
Case Comprehensive Cancer Center
Sapience Therapeutics
Mayo Clinic
BPGbio
NRG Oncology
Northwestern University
Karolinska Institutet
Case Comprehensive Cancer Center
Northwestern University